ABSTRACT
Metabolomics supports uncovering relevant pathophysiological mechanisms and identifying biomarkers of risk and progression in diseases. Furthermore, metabolomics has allowed the characterization of the proteins and metabolites of COVID-19, neurodegenerative processes, gestational diabetes mellitus, cancer breast, process of kidney transplantation, and Parkinson diagnosis, among other diseases (Table 7.1). Metabolomics employs noninvasive human biological samples such as serum, breath, and urine to screen and identify novel biomarkers. The combination of NMR, LC/MS, and CG/MS is desirable to detect, identify, and quantify hundreds of thousands of metabolites, useful in biomarker discovery toward clinical applications. The generation of biological information has led to the creation of databases such as BioBankWarden, which can be used to store and retrieve specific information from different clinical fields linked to biomaterials collected from patients. The use of metabolomics allows greater precision in the diagnosis and follow-up of the treatment of any disease. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.